micro-environmental signature of the interactions between druggable target protein, dipeptidyl peptidase-iv, and anti-diabetic drugs
نویسندگان
چکیده
objective: druggability of a target protein depends on the interacting micro-environment between the target protein and drugs. therefore, a precise knowledge of the interacting micro-environment between the target protein and drugs is requisite for drug discovery process. to understand such micro-environment, we performed in silico interaction analysis between a human target protein, dipeptidyl peptidase-iv (dpp-4), and three anti-diabetic drugs (saxagliptin, linagliptin and vildagliptin). materials and methods: during the theoretical and bioinformatics analysis of micro-environmental properties, we performed drug-likeness study, protein active site predictions, docking analysis and residual interactions with the protein-drug interface. micro-environmental landscape properties were evaluated through various parameters such as binding energy, intermolecular energy, electrostatic energy, van der waals'+h-bond+dissolve energy (evhd) and ligand efficiency (le) using different in silico methods. for this study, we have used several servers and software, such as molsoft prediction server, castp server, autodock software and ligplot server. results: through micro-environmental study, highest log p value was observed for linagliptin (1.07). lowest binding energy was also observed for linagliptin with dpp-4 in the binding plot. we also identified the number of h-bonds and residues involved in the hydrophobic interactions between the dpp-4 and the anti-diabetic drugs. during interaction, two h-bonds and nine residues, two h-bonds and eleven residues as well as four h-bonds and nine residues were found between the saxagliptin, linagliptin as well as vildagliptin cases and dpp-4, respectively. conclusion: our in silico data obtained for drug-target interactions and micro-environmental signature demonstrates linagliptin as the most stable interacting drug among the tested anti-diabetic medicines.
منابع مشابه
Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
OBJECTIVE Druggability of a target protein depends on the interacting micro-environment between the target protein and drugs. Therefore, a precise knowledge of the interacting micro-environment between the target protein and drugs is requisite for drug discovery process. To understand such micro-environment, we performed in silico interaction analysis between a human target protein, Dipeptidyl ...
متن کاملDipeptidyl Peptidase IV and Incident Diabetes
OBJECTIVE Dipeptidyl peptidase IV (DPP-IV) is not only important in beta-cell function but also has proinflammatory actions. We aimed to investigate whether it could act as a link between low-grade chronic inflammation and diabetes. RESEARCH DESIGN AND METHODS Using a case-cohort design, we followed 546 middle-aged individuals who developed diabetes and 538 who did not over approximately 9 ye...
متن کاملDipeptidyl peptidase IV inhibitors and diabetes therapy.
Current type 2 diabetes therapies are mainly targeted at stimulating pancreatic beta-cell secretion and reducing insulin resistance. A number of alternative therapies are currently being developed to take advantage of the actions of the incretin hormones Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP). These hormones are released from the small intestine i...
متن کاملTackling dipeptidyl peptidase IV in neurological disorders
Dipeptidyl peptidase IV (DPP-IV) is a serine protease best known for its role in inactivating glucagon-like peptide-1 (GLP-1), pituitary adenylate cyclase-activating polypeptide (PACAP) and glucose-dependent insulinotropic peptide (GIP), three stimulators of pancreatic insulin secretion with beneficial effects on glucose disposal. Owing to the relationship between DPP-IV and these peptides, inh...
متن کاملDifferential expression of dipeptidyl peptidase-IV (DPP-IV) in Indian type-2 diabetic population.
OBJECTIVES Dipeptidyl peptidase IV (CD26; E.C. 3.4.14.5) is plasma membrane glycoprotein exopeptidase. There are no data on both phenotypic or genotypic expression and polymorphism of DPP-IV in Indian type-2 diabetic patients. Therefore we estimated the dipeptidyl peptidase IV (DPP-IV) levels in Indian type 2 diabetic population. METHODS Selection of study group was as follows: 1. Twenty seve...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
cell journalجلد ۱۹، شماره ۱، صفحات ۶۵-۸۳
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023